The frequencies of peripheral blood CD5(+)CD19(+) B cells, CD3(-)CD16(+)CD56(+) NK, and CD3(+)CD56(+) NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
The frequencies of peripheral blood CD5(+)CD19(+) B cells, CD3(-)CD16(+)CD56(+) NK, and CD3(+)CD56(+) NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
复制标题
外周血CD5（+）CD19（+）B细胞的频率，CD3（ - ）CD16（+）CD56（+）NK和CD3（+）CD56（+）CD56（+）NKT细胞和血清白介素10的患者硬化症和神经瘤谱谱障碍。
DOI：
10.1186/s13223-021-00596-5
复制
发表时间：
2022-01-14
期刊：
影响因子：
--
通讯作者：
Ferns GA
中科院分区：
文献类型：
--
作者：
Khani L;Jazayeri MH;Nedaeinia R;Bozorgmehr M;Nabavi SM;Ferns GA
多发性硬化症（MS）和视神经脊髓炎综合征（NMOSD）是中枢神经系统的炎症性疾病。这两种情况的发病机制和治疗方法非常不同。自然杀伤 (NK) 和自然杀伤 T (NKT) 细胞是免疫细胞，在形成免疫反应中发挥着重要作用。 B 细胞参与抗原呈递以及抗体和细胞因子的产生。对于 NK、NKT 和 B 细胞在这两种情况下的作用，存在相互矛盾的证据。我们的目的是比较 MS 和 NMOSD 患者外周血和血清白细胞介素 10 (IL-10) 中 CD3−CD16+CD56+NK、CD3+ CD56+ NKT 和 CD5+CD19+ B 细胞的频率。通过流式细胞术对 15 名接受干扰素-β (IFN-β) 治疗的复发缓解型 MS (RRMS) 患者、15 名未经治疗的 RRMS 患者、15 名 NMOSD 患者以及 30 名健康对照 (HC) 患者的 CD19+CD5+ B、CD3− CD16+CD56+ NK 和 CD3+CD56+ NKT 细胞进行定量。使用酶联免疫吸附测定（ELISA）测量血清IL-10。 IFN治疗的MS外周血中CD3−CD56+CD16+ NK细胞的百分比（1.81±0.87）显着低于未治疗的RRMS（4.74±1.80）、NMOSD（4.64±±1.26）和HC（5.83±±2.19） (p < 0.0001)。 CD3−CD16+ 和 CD3−CD56+ 细胞的百分比也存在差异（分别为 p < 0.001 和 p < 0.0007）。研究组中，IFN 治疗的 RRMS (2.89±1.51) 的 CD3+CD56+ 比例最低 (p<0.002)。未经治疗的RRMS (5.56±3.04) 和NMOSD (5.47±1.24) 的CD3+CD56+ 水平高于HC (3.16±1.98)。未经治疗的RRMS患者外周血中CD19+CD5+B细胞的平均百分比（1.32±0.67）高于NMOSD（0.30±0.20）、HC（0.5±0.22）和IFN治疗的RRMS患者（0.81±0.17） (p < 0.0001)。与未经治疗的 RRMS (5.07±±1.44) 和 NMOSD 患者 (5.33±±2.56) 相比，经 IFN 治疗的 RRMS (8.06±±5.39) 和 HC (8.38±±2.84) 患者血清白细胞介素 10 显着升高（p < 0.003）。与其他组相比，经 IFN 治疗的 RRMS 患者外周血中 CD3−CD56+ CD16+ NK 和 CD3+CD56+ 细胞的比例较低，这表明免疫调节对 RRMS 疾病患者的重要性。基于患者和HC之间CD19+CD5+B细胞和血清IL-10的差异，补充评估对于阐明它们在自身免疫中的作用可能有价值。
Multiple sclerosis (MS) and neuromyelitis optica syndrome disease (NMOSD) are inflammatory diseases of the central nervous system. The pathogenesis and treatments for these two conditions are very different. Natural killer (NK) and natural killer T (NKT) cells are immune cells with an important role in shaping the immune response. B cells are involved in antigen presentation as well as antibody and cytokine production. There is conflicting evidence of the roles of NK, NKT, and B cells in the two conditions. We aimed to compare the frequency of CD3−CD16+CD56+NK, CD3+ CD56+ NKT, and CD5+CD19+ B cells in the peripheral blood and serum Interleukin-10 (IL-10) in patients with MS and NMOSD. CD19+CD5+ B, CD3− CD16+CD56+ NK, and CD3+CD56+ NKT cells were quantitated by flow cytometry in 15 individuals with Interferon-Beta (IFN-β) treated relapsing–remitting MS (RRMS), 15 untreated RRMS, and 15 NMOSD patients as well as 30 healthy controls (HC). Serum IL-10 was measured using an enzyme-linked immunosorbent assay (ELISA). The percentage of CD3−CD56+CD16+ NK cells in the peripheral blood of IFN-treated MS (1.81 ± 0.87) was significantly lower than for untreated RRMS (4.74 ± 1.80), NMOSD (4.64 ± 1.26) and HC (5.83 ± 2.19) (p < 0.0001). There were also differences for the percentage of CD3−CD16+ and CD3−CD56+ cells (p < 0.001 and p < 0.0007; respectively). IFN-treated RRMS (2.89 ± 1.51) had the lowest proportion of CD3+CD56+ among the study groups (p < 0.002). Untreated RRMS (5.56 ± 3.04) and NMOSD (5.47 ± 1.24) had higher levels of CD3+CD56+ than the HC (3.16 ± 1.98). The mean percentage of CD19+CD5+ B cells in the peripheral blood of untreated RRMS patients (1.32 ± 0.67) was higher compared to the patients with NMOSD (0.30 ± 0.20), HC (0.5 ± 0.22) and IFN-treated RRMS (0.81 ± 0.17) (p < 0.0001). Serum interleukin-10 was significantly higher in the IFN-treated RRMS (8.06 ± 5.39) and in HC (8.38 ± 2.84) compared to untreated RRMS (5.07 ± 1.44) and the patients with NMOSD (5.33 ± 2.56) (p < 0.003). The lower proportion of CD3−CD56+ CD16+ NK and CD3+CD56+ cells in peripheral blood of IFN-treated RRMS compared to other groups suggests the importance of immunomodulation in patients with RRMS disorder. Based on the differences in CD19+CD5+ B cells and serum IL-10 between patients and HC, supplementary assessments could be of value in clarifying their roles in autoimmunity.
登录
查看更多内容
影响因子：
12.8
作者：
Laroni, Alice;Armentani, Eric;Uccelli, Antonio
通讯作者：
Uccelli, Antonio
影响因子：
4.7
作者：
Kwilasz AJ;Grace PM;Serbedzija P;Maier SF;Watkins LR
通讯作者：
Watkins LR
影响因子：
5.4
作者：
Franitza, S;Grabovsky, V;Peled, A
通讯作者：
Peled, A
影响因子：
32.4
作者：
Kamanaka, Masahito;Kim, Sean T.;Flavell, Richard A.
通讯作者：
Flavell, Richard A.
影响因子：
3.7
作者：
Hoglund, Rune A.;Holmoy, Trygve;Maghazachi, Azzam A.
通讯作者：
Maghazachi, Azzam A.